CEFAZOLIN SODIUM FOR INJECTION BP POWDER FOR SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

CEFAZOLIN (CEFAZOLIN SODIUM)

Saatavilla:

STERIMAX INC

ATC-koodi:

J01DB04

INN (Kansainvälinen yleisnimi):

CEFAZOLIN

Annos:

1G

Lääkemuoto:

POWDER FOR SOLUTION

Koostumus:

CEFAZOLIN (CEFAZOLIN SODIUM) 1G

Antoreitti:

INTRAMUSCULAR

Kpl paketissa:

15G/50G

Prescription tyyppi:

Prescription

Terapeuttinen alue:

FIRST GENERATION CEPHALOSPORINS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0109442005; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2022-02-11

Valmisteyhteenveto

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CEFAZOLIN SODIUM FOR INJECTION BP
Powder for Solution, 1 gram, 2 grams and 10 grams Cefazolin (as
cefazolin sodium) per vial
Intravenous, Intramuscular
BP
Antibiotic
SteriMax Inc.
Date of Initial Authorization: JUN 24, 2020
2770 Portland Drive
Oakville, ON
Date of Revision: SEP 14, 2022
L6H 6R4
Control No: 263261
Pr
CEFAZOLIN SODIUM FOR INJECTION BP Page 2 of 21
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, SKIN
01/2021
7 WARNINGS AND PRECAUTIONS, RENAL
09/2022
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of
authorization are not listed.
RECENT MAJOR LABEL CHANGES
...............................................................................................
2
TABLE OF CONTENTS
.................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................................
4
1
INDICATIONS
......................................................................................................................
4
1.1
Pediatrics
..............................................................................................................................
5
1.2
Geriatrics
..............................................................................................................................
5
2
CONTRAINDICATIONS
.........................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.................................................................... 5
4.3
Reconstitution
......................................................................................................................
7
4.4
Administration
.................................................................................